TRV GP IV, LLC
CIK 1688325 · last filed 2025-10-27
TRV GP IV, LLC is a corporate insider who has filed 10 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $14.5M of TNGX on Oct 27, 2025. Across all open-market trades the lifetime net is −$94.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $301.5M across reported positions. The firm reports its address in Boston, MA. 36 SEC filings were submitted jointly with Third Rock Ventures GP IV, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$301.47M
2
10
-$94.40M
Filer Profile
BOSTON, MA 02215
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNGX | 10%+ Owner | 13,386,574 | $22.52 | $301.47M | -$85.23M | 8 | 2025-10-27 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | 10%+ Owner | 284,888 | $11.19 | $3.19M | -$9.17M | 2 | 2023-02-09 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-27 | TNGX | Sell (S) | −1,432,203 | -$14.54M | EDGAR |
| 2025-09-29 | TNGX | Sell (S) | −1,500,000 | -$12.03M | EDGAR |
| 2025-09-09 | TNGX | Sell (S) | −2,188,095 | -$15.33M | EDGAR |
| 2025-08-26 | TNGX | Sell (S) | −906,582 | -$6.35M | EDGAR |
| 2025-08-21 | TNGX | Sell (S) | −3,300,000 | -$23.14M | EDGAR |
| 2024-09-17 | TNGX | Sell (S) | −202,200 | -$2.13M | EDGAR |
| 2024-09-04 | TNGX | Sell (S) | −525,000 | -$6.09M | EDGAR |
| 2024-07-22 | TNGX | Sell (S) | −574,470 | -$5.64M | EDGAR |
| 2023-02-09 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Sell (S) | −11,100,000 | -$9.17M | EDGAR |
| 2021-08-26 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Other (J) | −3,750,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.